Ligand Pharmaceuticals (LGND) Total Current Liabilities (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Total Current Liabilities data on file, last reported at $40.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 30.7% year-over-year to $40.7 million; the trailing twelve-month figure through Mar 2026 stood at $40.7 million (down 30.7% YoY), and the FY2025 full-year result was $37.4 million, up 0.9% from the prior year.
• Total Current Liabilities improved to $40.7 million in Q1 2026, from $37.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $167.9 million in Q2 2022 to a low of $15.7 million in Q3 2023.
• A 5-year average of $55.0 million and a median of $37.4 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 272.6% in 2022 and tumbled 88.37% in 2023, its largest moves.
• Tracing LGND's Total Current Liabilities over 5 years: stood at $98.8 million in 2022, then tumbled by 83.02% to $16.8 million in 2023, then surged by 121.14% to $37.1 million in 2024, then climbed by 0.9% to $37.4 million in 2025, then increased by 8.6% to $40.7 million in 2026.
• Business Quant data shows LGND's Total Current Liabilities at $40.7 million in Q1 2026, $37.4 million in Q4 2025, and $30.5 million in Q3 2025.